147) te a suitable regression model with MI as response. |
148) shown to involve an ongoing inflammatory response. |
149) th substantial adaptation showed a bigger response. |
150) ed specifically the late rule-based motor response. |
151) that nondisclosure would be the normative response. |
152) nt the compression position-dependency in response. |
153) NA-78 was associated with sustained viral response. |
154) ry and triggering a systemic inflammatory response. |
155) by thrombus aspiration with good clinical response. |
156) sociated with lack of sustained virologic response. |
157) refighters that differed from the group's response. |
158) Now Aspirin for the assessment of aspirin response. |
159) dyle of the knee joint during the loading response. |
160) ts effect on Escherichia coli LPS-induced response. |
161) ntia risk by promoting neuronal and glial response. |
162) age, while developing pronounced adaptive response. |
163) f these molecules are mediators of immune response. |
164) n (HBeAg) would more likely develop worse response. |
165) replication and the associated DNA damage response. |
166) tro group were strong inducers of the SOS response. |
167) l's degradation kinetics and in vivo host response. |
168) in dysphagia score after an initial good response. |
169) Col group over the same period showed no response. |
170) course and the activation of a microglial response. |
171) ic effects of QTLs on correlative plastic response. |
172) most important in predicting intervention response. |
173) is a potential inducer of a specific IgE response. |
174) vous system following a neuroinflammatory response. |
175) o and thus contribute to the inflammatory response. |
176) inflammatory and anti-inflammatory immune response. |
177) s during the mounting of an innate immune response. |
178) o the PPC modulated only the early mirror response. |
179) f cilengitide on platelet pro-coagulative response and adhesion is of interest. |
|